N/A
N=9
Safety and Efficacy of Valiant Mona LSA Stent Graft System
Thoracic Aortic Aneurysms
Bottom Line
View on ClinicalTrials.gov: NCT01839695 ↗Enrolled (actual)
9
Serious AEs
77.8%
Results posted
Oct 2014
Primary outcome: Primary: Primary Safety Observation - Rate of Major Adverse Events (MAEs) — 3 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Valiant Mona LSA Stent Graft System (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medtronic Cardiovascular
- Primary completion
- Feb 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Primary Safety Observation - Rate of Major Adverse Events (MAEs) |
3 | — |
| PRIMARY Primary Effectiveness Observation |
8 | — |
Summary
The Valiant Mona LSA thoracic stent graft system is for the endovascular repair of aneurysms of the descending thoracic aorta (DTA) in patients who require coverage of the left subclavian artery (LSA).The study is intended to assess safety and performance of the device acutely and at 30 days.
Eligibility Criteria
Inclusion Criteria
- Subject is at least 18 years of age.
- The subject or legal guardian understands the nature of the study and agrees to its provisions on a written informed consent form
- Subject must be considered a candidate for revascularization of the LSA.
- Subject has a DTA which will require coverage of the LSA
- Subject's anatomy must meet the anatomical criteria to receive that implanted device
Exclusion Criteria
- Subject has had previous endovascular repair of the ascending and/or descending thoracic aorta.
- Subject is in acute renal failure or has renal insufficiency with a serum creatinine ≥ 2.0 mg/dL
- Subject is a pregnant female.
- Enrollment in another clinical study
- Subject has had a cerebral vascular accident (CVA)or myocardial infarction (MI) within 3 months.
- Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.
- Subject has a known allergy or intolerance to the device components.
- Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.
Data sourced from ClinicalTrials.gov (NCT01839695). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.